HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.

Abstract
With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is uniformly lethal in Hartley guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influenza, has potent activity against LASV infection. In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue samples and reduced mortality rates when compared with animals receiving vehicle-only or ribavirin, the current standard of care for Lassa fever. Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. These results support the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.
AuthorsDavid Safronetz, Kyle Rosenke, Jonna B Westover, Cynthia Martellaro, Atsushi Okumura, Yousuke Furuta, Joan Geisbert, Greg Saturday, Takashi Komeno, Thomas W Geisbert, Heinz Feldmann, Brian B Gowen
JournalScientific reports (Sci Rep) Vol. 5 Pg. 14775 (Oct 12 2015) ISSN: 2045-2322 [Electronic] England
PMID26456301 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
Chemical References
  • Amides
  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulin G
  • Pyrazines
  • Ribavirin
  • favipiravir
Topics
  • Amides (pharmacology)
  • Animals
  • Animals, Outbred Strains
  • Antibodies, Viral (biosynthesis, blood)
  • Antiviral Agents (pharmacology)
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Guinea Pigs
  • Humans
  • Immunoglobulin G (biosynthesis, blood)
  • Lassa Fever (drug therapy, immunology, mortality, virology)
  • Lassa virus (drug effects, pathogenicity, physiology)
  • Liver (drug effects, virology)
  • Lung (drug effects, virology)
  • Male
  • Pyrazines (pharmacology)
  • Ribavirin (pharmacology)
  • Spleen (drug effects, pathology, virology)
  • Survival Analysis
  • Viral Load (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: